Regulus Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Regulus Therapeutics generated cash of -$26,768,000, which is less than the previous year. Cash used in financing activities reached the amount of $11,816,000 last year. Net change in cash is therefore -$461,000.
Cash Flow
| 2014 | -39.51M | -29.20M | 88.23M |
|---|---|---|---|
| 2015 | -49.85M | 21.47M | 7.01M |
| 2016 | -56.88M | 35.31M | 20.55M |
| 2017 | -58.77M | 13.93M | 43.41M |
| 2018 | -43.27M | 46.51M | -2.83M |
| 2019 | -19.82M | 74K | 39.93M |
| 2020 | -12.53M | -11K | 9.51M |
| 2021 | -24.12M | -251K | 53.73M |
| 2022 | -25.52M | -15.12M | 4.49M |
| 2023 | -26.76M | 14.49M | 11.81M |
RGLS Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 24.29M | 60.44M | 31.08M | 34.12M | 13.93M | 13.51M | 14.94M | 15.96M | 37.32M | 17.80M |
Operating activities | ||||||||||
Net income | -30.03M | -28.32M | -27.80M | -15.73M | -18.59M | -48.70M | -71.90M | -81.83M | -55.74M | -56.68M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 227K | 122K | 459K | 467K | 931K | 2.26M | 2.52M | 2.27M | 1.59M | 1.49M |
Stock-based compensation expense | 2.80M | 2.17M | 2.92M | 2.61M | 2.28M | 0 | 7.64M | 12.87M | 15.36M | 7.03M |
| Deferred income tax benefit | 2.80M | 2.17M | 2.92M | 2.61M | 2.28M | 0 | 7.64M | 12.87M | 15.36M | 7.03M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 503K | 638K | -1.11M | 347K | 1.28M | 6.64M | -9.74M | 0 |
Inventories | 0 | 0 | 304 | 610 | 270 | -606K | 394K | -616K | -3.46M | 0 |
Accounts payable | 29K | -110K | -250K | -786K | -393K | -4.02M | -65K | 3.12M | 529K | 940K |
Cash generated by operating activities | -26.76M | -25.52M | -24.12M | -12.53M | -19.82M | -43.27M | -58.77M | -56.88M | -49.85M | -39.51M |
Investing activities | ||||||||||
Purchases Of Investments | -4.89M | -32.75M | 0 | 0 | 0 | 0 | -55.68M | -65.11M | -78.40M | -113.41M |
Investments In Property Plant And Equipment | -613K | -361K | -251K | -11K | -244K | -22K | -319K | -966K | -1.43M | -1.21M |
Acquisitions Net | 0 | 14.75K | 0 | 0 | 318K | 0 | 16K | 53K | 67K | 65K |
Cash generated by investing activities | 14.49M | -15.12M | -251K | -11K | 74K | 46.51M | 13.93M | 35.31M | 21.47M | -29.20M |
Financing activities | ||||||||||
Common Stock Issued | 15.12M | 4.49M | 53.79M | 19.12M | 42.17M | 219K | 43.41M | 641K | 7.17M | 88.37M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -3.30M | 0 | -80K | -10.27M | -2.24M | -3.34M | 0 | -167K | 0 | 0 |
Cash used in financing activities | 11.81M | 4.49M | 53.73M | 9.51M | 39.93M | -2.83M | 43.41M | 20.55M | 7.01M | 88.23M |
Net Change In Cash | -461K | -36.15M | 29.35M | -3.03M | 20.18M | 416K | -1.42M | -1.01M | -21.36M | 19.52M |
Cash at end of period | 23.82M | 24.29M | 60.44M | 31.08M | 34.12M | 13.93M | 13.51M | 14.94M | 15.96M | 37.32M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |